DBV Technologies (FR:DBV)
:DBV
Top Page
DBV Technologies
(DBV)
Select Model
Select Model
Rating:45Neutral
Price Target:
€3.50
▼(-9.09% Downside)
Action:ReiteratedDate:03/27/26
The score is held down primarily by very weak financial performance (large ongoing losses and significant cash burn), which implies continued external funding risk. Technicals are mixed with soft near-term momentum but some longer-term support, while valuation metrics are not very informative due to negative earnings and no dividend yield data.
Positive Factors
Successful Phase 3 data
A positive Phase 3 readout materially strengthens the clinical case for Viaskin Peanut and validates DBV’s EPIT approach. This reduces binary clinical risk, improves prospects for regulatory approval and commercialization, and supports future partnerships or licensing opportunities.
Negative Factors
High cash burn
Sustained ~-$122M TTM free cash flow indicates material funding needs. Persistent cash burn forces repeated financing, increasing dilution risk and distracting management with capital raises. Absent meaningful revenue ramp, spending cuts or large financing, runway and execution risk remain elevated.
Read all positive and negative factors
Positive Factors
Negative Factors
Successful Phase 3 data
A positive Phase 3 readout materially strengthens the clinical case for Viaskin Peanut and validates DBV’s EPIT approach. This reduces binary clinical risk, improves prospects for regulatory approval and commercialization, and supports future partnerships or licensing opportunities.
Read all positive factors
DBV Technologies (DBV) vs. iShares MSCI France ETF (EWQ)
Market Cap
€1.01B
Dividend YieldN/A
Average Volume (3M)1.12M
Price to Earnings (P/E)―
Beta (1Y)0.63
Revenue GrowthN/A
EPS Growth3.09%
CountryFR
Employees106
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding278,352,080
10 Day Avg. Volume2,165,856
30 Day Avg. Volume1,121,838
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)3.28
Price to Sales (P/S)0.00
P/FCF Ratio-4.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.26Price Target Upside-15.32% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-0.17
Revenue Forecast (FY)€4.60M
DBV Technologies Business Overview & Revenue Model
Company Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase II...
How the Company Makes Money
null...
DBV Technologies Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 4.15M | 15.73M | 4.80M | 5.71M |
| Gross Profit | -18.34M | 4.15M | 15.73M | -15.50M | -3.57M |
| EBITDA | -140.58M | 0.00 | -87.46M | -76.68M | -79.77M |
| Net Income | -152.94M | -113.92M | -72.73M | -96.30M | -97.81M |
Balance Sheet | |||||
| Total Assets | 233.75M | 65.66M | 182.99M | 246.50M | 146.72M |
| Cash, Cash Equivalents and Short-Term Investments | 194.19M | 32.46M | 141.37M | 209.20M | 77.30M |
| Total Debt | 21.69M | 7.80M | 6.55M | 4.15M | 9.74M |
| Total Liabilities | 64.96M | 38.27M | 42.80M | 52.00M | 47.45M |
| Stockholders Equity | 168.79M | 27.39M | 140.19M | 194.50M | 99.27M |
Cash Flow | |||||
| Free Cash Flow | -126.68M | -106.81M | -80.33M | -56.45M | -109.16M |
| Operating Cash Flow | -126.12M | -104.47M | -79.65M | -55.70M | -108.24M |
| Investing Cash Flow | -1.42M | -757.00K | -808.00K | -100.00K | -433.00K |
| Financing Cash Flow | 287.44M | 587.00K | 6.77M | 194.10M | 274.00K |
DBV Technologies Technical Analysis
Positive
3.85
Price Trends
3.66
Negative
3.38
Positive
2.67
Positive
Market Momentum
-0.01
Negative
51.17
Neutral
44.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:DBV, the sentiment is Positive. The current price of 3.85 is above the 20-day moving average (MA) of 3.52, above the 50-day MA of 3.66, and above the 200-day MA of 2.67, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 51.17 is Neutral, neither overbought nor oversold. The STOCH value of 44.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:DBV.
DBV Technologies Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | €213.76M | -3.69 | -634.16% | ― | 111.76% | -22.45% | |
49 Neutral | €70.52M | -1.87 | -52.76% | ― | -96.92% | -175.84% | |
49 Neutral | €839.42M | -12.22 | ― | ― | 166.31% | 43.80% | |
46 Neutral | €453.97M | -5.43 | -58.93% | ― | 13.48% | -1299.09% | |
45 Neutral | €1.01B | -3.62 | -241.12% | ― | ― | 3.09% | |
44 Neutral | €112.19M | -2.91 | -658.91% | ― | -75.86% | -30.54% |
* General Sector Average
FR:DBV
DBV Technologies
3.85
2.54
193.30%
FR:IPH
Innate Pharma SA
1.36
-0.42
-23.60%
FR:TNG
Transgene
0.76
0.12
18.44%
FR:VLA
Valneva
2.64
-0.54
-17.06%
FR:OSE
OSE Immunotherapeutics SA
3.24
-2.51
-43.65%
FR:MEDCL
MedinCell SA
25.12
11.10
79.17%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.